Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst

Key Points

• HC Wainwright lowered Oruka Therapeutics’ Q3 2026 EPS estimate to a loss of $0.66 per share from $0.47, while maintaining a “Buy” rating and $120 price target.
• Oruka reported a Q2 loss of $0.55 per share, missing the $0.51 consensus estimate. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $133.
• The stock opened at $92.51, with a market capitalization of roughly $6.13 billion. Insiders sold 158,116 shares worth $13.5 million over the past 90 days, while institutional investors own 56.44% of the shares.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2026 earnings estimates for Oruka Therapeutics in a research report issued to clients and investors on Thursday, September 3rd. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.66) per share for the quarter, down from their prior forecast of ($0.47). HC Wainwright has a "Buy" rating and a $120.00 price objective on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.54) EPS, Q1 2027 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.72) EPS and FY2027 earnings at ($2.82) EPS.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04).

Other equities analysts have also issued reports about the company. UBS Group upped their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday, July 1st. BTIG Research restated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wedbush reissued an "outperform" rating and issued a $165.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reiterated an "overweight" rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen cut shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $133.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $92.51 on Monday. The company has a fifty day moving average price of $95.24 and a 200 day moving average price of $69.84. Oruka Therapeutics has a one year low of $14.66 and a one year high of $115.51. The stock has a market cap of $6.13 billion, a P/E ratio of -45.57 and a beta of -0.34.

Insider Transactions at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 12,583 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the transaction, the senior vice president directly owned 15,312 shares of the company's stock, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 158,116 shares of company stock valued at $13,523,783. 23.49% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ORKA. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $28,000. Nykredit A S acquired a new stake in Oruka Therapeutics in the 2nd quarter worth about $29,000. BNP Paribas Financial Markets raised its holdings in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after acquiring an additional 2,306 shares in the last quarter. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after buying an additional 365 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. 56.44% of the stock is owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source